Press Releases

Marizyme Inc. Announces Results of GOAL Study Presented at 7th Annual International Coronary Congress

Dec 3, 2021

Marizyme Announces Expansion of Patent Portfolio Into Several Key Territories

Dec 3, 2021

Marizyme is Pleased to Announce
the Appointment of David Barthel
as CEO

Nov 16, 2021

Marizyme, Inc.
Issues Letter to
Shareholders

Mar 31, 2021

Marizyme Announces New Distribution and Channel Partnership for Chilean Market with Abdera

Mar 04, 2021

Marizyme, Inc. Appoints Veteran Business Executive Julie Kampf
to Board

Feb 04, 2021

Marizyme, Inc. Appoints 2
Senior Management
Personnel

Feb 01, 2021

Marizyme Announces Approval
for DuraGraft®
in India

Jan 14, 2021

Marizyme, Inc. Expands
Executive Team, Board
of Directors

Dec 04, 2020

Marizyme, Inc. Appoints Dr. Neil J. Campbell, as CEO, President and Member of Board of Directors

Nov 06, 2020

Marizyme and SBH Nutrition Science Agree to Develop Krillase(R) Based Dental Products for Pets

Oct 27, 2020

Marizyme, Inc. Announces
European Duragraft Registry
Results

Oct 9, 2020

Univest Securities, LLC. Announces Closing of Somulation, Inc. Acquisition and $7 Million Private Placement for its Client Marizyme, Inc.

Sep 29, 2020

Marizyme, Inc. Completes Acquisition of Somahlution, Inc. and Raises
$7.0 Million in Private
Placement

Sep 29, 2020

Marizyme, Inc., Engages Dr. Pamela
Milla as Advisor to Begin
Distribution in South
America

Apr 26, 2020

Marizyme and Somahlution
Announce Agreement with
Leipzig Heart
Center

Apr 8, 2020

2021

Marizyme Inc. Announces Results of GOAL Study Presented at 7th Annual International Coronary Congress

Marizyme Announces Expansion of Patent Portfolio Into Several Key Territories

Marizyme is Pleased to Announce
the Appointment of David Barthel
as CEO

Marizyme, Inc.
Issues Letter to
Shareholders

Marizyme Announces New Distribution and Channel Partnership for Chilean Market with Abdera

Marizyme, Inc. Appoints Veteran Business Executive Julie Kampf
to Board

Marizyme, Inc. Appoints 2
Senior Management
Personnel

Marizyme Announces Approval
for DuraGraft®
in India

Marizyme Announces the Use of DuraGraft® as the Standard-of-Care in Patients Undergoing Coronary Artery Bypass Surgery (CABG) at Vienna Heart Center North Floridsdorf

Marizyme, Inc. to Present at Biotech Showcase 2021 During the J.P. Morgan Healthcare Conference Biotech Showcase Digital, BIO @ JPM During “J.P. Morgan Week 2021”

2020

Marizyme, Inc. Expands
Executive Team, Board
of Directors

Marizyme, Inc. Appoints Dr. Neil J. Campbell, as CEO, President and Member of Board of Directors

Marizyme and SBH Nutrition Science Agree to Develop Krillase(R) Based Dental Products for Pets

Marizyme, Inc. Announces
European Duragraft Registry
Results

Univest Securities, LLC. Announces Closing of Somulation, Inc. Acquisition and $7 Million Private Placement for its Client Marizyme, Inc.

Marizyme, Inc. Completes Acquisition of Somahlution, Inc. and Raises
$7.0 Million in Private
Placement

Marizyme, Inc., Engages Dr. Pamela
Milla as Advisor to Begin
Distribution in South
America

Marizyme and Somahlution
Announce Agreement with
Leipzig Heart
Center

Marizyme, Inc. Hires Ralph Makar as Chief Executive Officer

Duragraft Receives SGK National Reimbursement in Turkey

2019

Marizyme, Inc. Agrees to Acquire All Assets of Somahlution

Distribution of DuraGraft Products in South America and Mexico

OTC Markets Group Welcomes New OTCQB Companies

Explore

Explore

Press Releases

2021

Marizyme Inc. Announces Results of GOAL Study Presented at 7th Annual International Coronary Congress

Marizyme Announces Expansion of Patent Portfolio Into Several Key Territories

Marizyme is Pleased to Announce the Appointment of David Barthel as CEO

Marizyme, Inc. Issues Letter to Shareholders

Marizyme Announces New Distribution and Channel Partnership for Chilean Market with Abdera

Marizyme, Inc. Appoints Veteran Business Executive Julie Kampf to Board

Marizyme, Inc. Appoints 2 Senior Management Personnel

Marizyme Announces Approval for DuraGraft® in India

Marizyme Announces the Use of DuraGraft® as the Standard-of-Care in Patients Undergoing Coronary Artery Bypass Surgery (CABG) at Vienna Heart Center North Floridsdorf

Marizyme, Inc. to Present at Biotech Showcase 2021 During the J.P. Morgan Healthcare Conference Biotech Showcase Digital, BIO @ JPM During “J.P. Morgan Week 2021”

2020

Marizyme, Inc. Expands Executive Team, Board of Directors

Marizyme, Inc. Appoints Dr. Neil J. Campbell, as CEO, President and Member of Board of Directors

Marizyme and SBH Nutrition Science Agree to Develop Krillase(R) Based Dental Products for Pets

Marizyme, Inc. Announces European Duragraft Registry Results

Univest Securities, LLC. Announces Closing of Somulation, Inc. Acquisition and $7 Million Private Placement for its Client Marizyme, Inc.

Marizyme, Inc. Completes Acquisition of Somahlution, Inc. and Raises $7.0 Million in Private Placement

Marizyme, Inc., Engages Dr. Pamela Milla as Advisor to Begin Distribution in South America

Marizyme and Somahlution Announce Agreement with Leipzig Heart Center

Marizyme, Inc. Hires Ralph Makar as Chief Executive Officer

Duragraft Receives SGK National Reimbursement in Turkey

2019

Marizyme, Inc. Agrees to Acquire All Assets of Somahlution

Distribution of DuraGraft Products in South America and Mexico

OTC Markets Group Welcomes New OTCQB Companies

Explore

Explore

Marizyme is Pleased to Announce
the Appointment of David Barthel
as CEO

Marizyme, Inc.
Issues Letter to
Shareholders

Marizyme, Inc. Appoints Veteran Business Executive Julie Kampf
to Board

Marizyme, Inc. Appoints 2
Senior Management
Personnel

Marizyme Announces Approval
for DuraGraft®
in India

Marizyme, Inc. Expands
Executive Team, Board
of Directors

Marizyme, Inc. Announces
European Duragraft Registry
Results

Marizyme, Inc. Completes Acquisition of Somahlution, Inc. and Raises
$7.0 Million in Private
Placement

Marizyme, Inc., Engages Dr. Pamela
Milla as Advisor to Begin
Distribution in South
America

Marizyme and Somahlution
Announce Agreement with
Leipzig Heart
Center